uniQure (NASDAQ:QURE) Given New $65.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus has raised its price target for uniQure from $30.00 to $65.00, indicating a potential upside of 35.84%, while maintaining a "buy" rating on the stock.
• April 2023 saw a significant trading surge for uniQure, with shares increasing by 250.3% and reaching a trading price of $47.85.
• Major institutional investors have heavily increased their stakes in uniQure, with notable purchases including Jefferies Financial Group's new position valued at approximately $29.2 million.

uniQure (NASDAQ:QURE - Get Free Report) had its price objective upped by Stifel Nicolaus from $30.00 to $65.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Stifel Nicolaus' target price would indicate a potential upside of 35.84% from the stock's current price.

Other analysts have also issued research reports about the company. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Leerink Partners increased their price objective on shares of uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a report on Wednesday. Mizuho upgraded shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price on the stock in a report on Thursday, August 14th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Wednesday. Finally, Cantor Fitzgerald set a $47.00 price objective on uniQure in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $42.64.

uniQure Trading Up 250.3%

NASDAQ:QURE traded up $34.19 during trading hours on Wednesday, hitting $47.85. The company had a trading volume of 61,605,254 shares, compared to its average volume of 1,686,035. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. uniQure has a 52 week low of $4.45 and a 52 week high of $51.21. The company has a market capitalization of $2.63 billion, a PE ratio of -12.00 and a beta of 0.14. The stock has a 50-day moving average price of $15.24 and a 200 day moving average price of $14.09.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. On average, equities research analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several large investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. purchased a new position in uniQure during the 2nd quarter worth $29,217,000. Vestal Point Capital LP increased its stake in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the period. JPMorgan Chase & Co. raised its holdings in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Sofinnova Investments Inc. lifted its position in uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the period. Finally, Aberdeen Group plc boosted its holdings in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after purchasing an additional 706,216 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.